Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd Q4 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The investor presentation reports the following for the quarter: - Revenue: $1.2 billion, representing a 5% increase year-on-year. EBITDA: ₹5,750 crore, up 13% YoY - Operating Margin: 42.5%, up 180 basis points YoY - Profit After Tax (PAT): ₹3,193 crore, up 37% YoY - Margin Outlook: The presentation explicitly
From Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points management made on revenue & sales performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹187 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY25 investor presentation — and how it ranks against sector p
- Kopran Ltd (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key investor presentation takeaways from Kopran Ltd's Q4 FY25 investor presentation — and how it ranks against sector peers.
- Fermenta Biotech Ltd (Q4 FY25)
Q4 FY25 Revenue: ₹143.7 crore . Key investor presentation takeaways from Fermenta Biotech Ltd's Q4 FY25 investor presentation — and how it ranks against sector
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q4 FY25 results?
The investor presentation reports the following for the quarter: - Revenue: $1.2 billion, representing a 5% increase year-on-year. EBITDA: ₹5,750 crore, up 13% YoY - Operating Margin: 42.5%, up 180 basis points YoY - Profit After Tax (PAT): ₹3,193 crore, up 37% YoY - Margin Outlook: The presentation explicitly
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The presentation does not provide any specific information regarding capex, capacity expansion, or new plant/project details, including amounts, status, or timelines.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.